Home/Pipeline/VBI-2901

VBI-2901

COVID-19

Phase 1Active

Key Facts

Indication

COVID-19

Phase

Phase 1

Status

Active

Company

VBI Vaccines

About VBI Vaccines

VBI Vaccines is a biopharmaceutical company founded on an innovative eVLP technology platform designed to elicit potent and broad immune responses. Its historical achievement was the U.S. approval and commercialization of PreHevbrio, a three-antigen hepatitis B vaccine, but the company has since ceased commercial operations and entered restructuring proceedings under the CCAA in Canada. Its current strategy is to preserve capital, review strategic alternatives, and advance its most promising clinical-stage assets in cytomegalovirus (CMV) prevention and glioblastoma (GBM) treatment through this period of financial distress.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
Adjuvanted Cell-Based COVID-19 Vaccine	CSL Seqirus	Marketed	Commercial (region-dependent)
Sequential Dialysis Technique	Halberd	Discovery	Conceptual / Dormant
Amubarvimab + Romlusevimab (BRII-196/BRII-198)	Brii Biosciences	Approved	Commercial (China)
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active